Trial · NCT02472223
Reducing Adenoviral Patient Infected Days
NCT02472223, Not applicable, Completed, Washington University School of Medicine; results first posted 2021-01-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reducing Adenoviral Patient Infected Days. Trials, record NCT02472223. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02472223
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reducing Adenoviral Patient Infected Days
- NCT number
- NCT02472223
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 28 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Conjunctivitis, Adenoviral Conjunctivitis
- Interventions
- Betadine 5%, Artificial Tears
- First posted
- 2015-06-15
- Last updated
- 2021-01-06
- Results first posted
- 2021-01-06
- Limitations and caveats
Small pilot study. Sample consisting of only adults. Lost to follow-up. High false positive rate of point-of-care immunoassay which necessitated a modified intention-to-treat analysis of participants with PCR confirmed Ad-Cs.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change From Peak Viral Load | 21 days | To compare efficacy of Betadine 5% to artificial tears to change from peak viral load in Adenoviral conjunctivitis |
| Secondary | Participant Reported Bothersomeness of Ocular Symptoms | 21 days | Participants reported bothersomeness of ocular symptoms on a 10 point scale 0=not at all. 10=very bothersome |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change From Peak Viral Load | 21 days | Subgroup of 16 patients randomized to Betadine and 12 patients randomized to artificial tears who tested positive for adenoviral conjunctivitis by qPCR at baseline. Viral load was assessed at baseline, post treatment follow-up days at 1-2, 4-5, 7, 14 and 21. | Percent of peak Viral Load | MEDIAN |
| SECONDARY | Participant Reported Bothersomeness of Ocular Symptoms | 21 days | Patient reported bothersomeness of ocular symptoms was assessed at baseline, post treatment follow-up days at 1-2, 4-5, 7, 14 and 21. | Unit on a scale | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Peak Viral Load | Betadine 5% | 1.9 | Full Range 0 to 7.6 | Percent of peak Viral Load | |
| Percent Change From Peak Viral Load | Artificial Tears | 13.2 | Full Range 1 to 32.3 | Percent of peak Viral Load | |
| Participant Reported Bothersomeness of Ocular Symptoms | Betadine 5% | 4.5 | Full Range 0 to 10 | Unit on a scale | |
| Participant Reported Bothersomeness of Ocular Symptoms | Artificial Tears | 8.0 | Full Range 0 to 10 | Unit on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Betadine 5% | 16 | |
| Overall Study | STARTED | Artificial Tears | 12 | |
| Overall Study | COMPLETED | Betadine 5% | 10 | |
| Overall Study | COMPLETED | Artificial Tears | 7 | |
| Overall Study | NOT COMPLETED | Betadine 5% | 6 | |
| Overall Study | NOT COMPLETED | Artificial Tears | 5 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Betadine 5% | 1 | 16 |
| Total, all-cause mortality | Artificial Tears | 0 | 12 |
| Total, other adverse events | Betadine 5% | 0 | 16 |
| Total, other adverse events | Artificial Tears | 0 | 12 |
| Total, serious adverse events | Betadine 5% | 0 | 16 |
| Total, serious adverse events | Artificial Tears | 0 | 12 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Betadine 5% vs Artificial Tears: deaths from any cause | Trial comparisons |
| Betadine 5% vs Artificial Tears: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02472223
GET https://conductscience.org/api/trials/v1/NCT02472223/registered